Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04308954 · ClinicalTrials.gov registry record · Phase 1
Neuroimaging GABA Physiology in Fragile X Syndrome
A Phase 1 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT04308954: Clinical Trial Phase 1 study, sponsored by Stanford University.
NCT04308954 is a Phase 1 study that was terminated before completion, run by Stanford University. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04308954, a Phase 1 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
The investigators wish to compare the brain distribution of GABA(A) receptors and GABA levels in young adult males with Fragile X Syndrome compared to idiopathic intellectual developmental disorder. The radiopharmaceutical \[18F\]flumazenil has been used to study GABA(A) receptor distribution in other genetic syndromes with autistic features; however, despite overwhelming evidence supporting the importance of the GABAergic system in FXS, no clinical investigation of this system in human FXS has been reported in the literature. Therefore, this study will provide the first in vivo comprehensive examination of the GABAergic system in FXS using hybrid positron emission tomography/ magnetic resonance imaging (PET/MRI).
Interventions
- DRUG [18F]flumazenil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2016-11-01 |
| Est. Completion | 2018-12-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04308954
The ClinicalTrials.gov registry entry for NCT04308954 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [18F]flumazenil is the first listed.
NCT04308954 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04308954 about?
NCT04308954 is a clinical study titled "Neuroimaging GABA Physiology in Fragile X Syndrome". The investigators wish to compare the brain distribution of GABA(A) receptors and GABA levels in young adult males with Fragile X Syndrome compared to idiopathic intellectual developmental disorder. The radiopharmaceutical \[18F\]flumazenil has been used to study GABA(A) receptor distribution in oth...
What is the current status of trial NCT04308954?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2016-11-01. Estimated completion is 2018-12-06.
What interventions are being tested in trial NCT04308954?
The interventions under investigation include: [18F]flumazenil (DRUG).
Who is sponsoring clinical trial NCT04308954?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.